Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KRAS G12D Copanlisib + Refametinib biliary tract cancer sensitive detail...
KRAS wild-type Panitumumab + Gemcitabine + Oxaliplatin biliary tract cancer predicted - sensitive detail...
SRC positive Bosutinib biliary tract cancer sensitive detail...
SRC positive Bosutinib + Gemcitabine biliary tract cancer sensitive detail...
SRC positive Bosutinib + Cisplatin biliary tract cancer sensitive detail...
Unknown unknown Binimetinib biliary tract cancer not applicable detail...
NRAS mutant Binimetinib biliary tract cancer predicted - sensitive detail...
ERBB2 over exp HER2 CAR-T cells biliary tract cancer predicted - sensitive detail...
FGFR2 fusion TAS-120 biliary tract cancer predicted - sensitive detail...
ERBB2 mutant Neratinib biliary tract cancer predicted - sensitive detail...
ERBB2 L755S Neratinib biliary tract cancer no benefit detail...
ERBB2 S310F Neratinib biliary tract cancer no benefit detail...
ERBB2 T733I Neratinib biliary tract cancer no benefit detail...
ERBB2 V659E Neratinib biliary tract cancer no benefit detail...
ERBB2 V777L Neratinib biliary tract cancer no benefit detail...
Unknown unknown Ramucirumab biliary tract cancer not applicable detail...
Unknown unknown PTC-209 biliary tract cancer not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab biliary tract cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab biliary tract cancer predicted - sensitive detail...
ERBB2 act mut Pertuzumab + Trastuzumab biliary tract cancer predicted - sensitive detail...
Unknown unknown Pembrolizumab biliary tract cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01828034 Phase Ib/II MEK162 + Gemcitabine + Cisplatin First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma Active, not recruiting
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Active, not recruiting
NCT02034110 Phase II Trametinib + Dabrafenib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02053376 Phase II Regorafenib A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed
NCT02091141 Phase II Erlotinib Alectinib Vemurafenib + Cobimetinib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Recruiting
NCT02105350 Phase I Gemcitabine + MEK162 + Oxaliplatin A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer Withdrawn
NCT02151084 Phase II Selumetinib + Cisplatin + Gemcitabine A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Active, not recruiting
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Recruiting
NCT02265341 Phase II Ponatinib Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Active, not recruiting
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated
NCT02451553 Phase I Afatinib Capecitabine Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Recruiting
NCT02452970 Phase II RRx-001 Gemcitabine + Cisplatin RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Active, not recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02576431 Phase II Larotrectinib Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Recruiting
NCT02703714 Phase II Pembrolizumab + Sargramostim Pembrolizumab and GM-CSF in Biliary Cancer Recruiting
NCT02711553 Phase II Ramucirumab Merestinib Gemcitabine + Cisplatin A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT02795156 Phase II Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02821754 Phase Ib/II Durvalumab + Tremelimumab A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Recruiting
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Recruiting
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT03101566 Phase II Cisplatin + Gemcitabine + Nivolumab Nivolumab + Ipilimumab Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Recruiting
NCT03111732 Phase II Capecitabine + Oxaliplatin + Pembrolizumab Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Recruiting
NCT03337087 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib Phosphate in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting
NCT03482102 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Recruiting
NCT03639935 Phase II Nivolumab + Rucaparib Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Recruiting
NCT03684811 Phase Ib/II Cisplatin + FT-2102 + Gemcitabine FT-2102 + Azacitidine FT-2102 FT-2102 + Nivolumab A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Recruiting
NCT03768531 Phase II Cabiralizumab + Nivolumab Nivolumab Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer Not yet recruiting
NCT03785873 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Nivolumab Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer Not yet recruiting
NCT03833661 Phase II M7824 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) Not yet recruiting
NCT03875235 Phase III Gemcitabine + Cisplatin Cisplatin + Durvalumab + Gemcitabine A Global Phase III Study of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Not yet recruiting